Lenalidomide
From Ganfyd
rINN: Lenalidomide
Other Names
Revlimid®
Pharmacological Information
Pharmacology Images
Web information on Lenalidomide
Relevant Clinical Literature
UK Guidance
Regulatory Literature
Other Literature
Please read pharmacological data limitations
Other Wikis
Medpedia on Lenalidomide (Less technical, good quality control)
Wikipedia on Lenalidomide (Less technical, ? quality control)
Contents |
Introduction
Used in treatment of multiple myeloma. Similar to thalidomide, but with more favorable side-effect profile.[1] The main barrier to increased use is its cost premium over thalidomide..
Clinical Use
Indications
- Multiple myeloma
- Note: EU license for anaemia caused by myelodysplastic syndromes associated with deletion of 5q, refused June 2008. Was approved in Switzerland in November 2011 for anaemia caused by low-or intermediate-1-risk myelodysplastic syndromes.
Administration
Oral
Clinical Issues
 | In a wide range of multiple myeloma indications lenalidomide:
|
Contra-indications
Cautions and Interactions
Side effects
- Risk of VTE
- Associated with increased incidence of secondary cancer
Special advice
Pharmacology
A tumour necrosis factor alpha (TNF-α) inhibitor.
References
- ↑ Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, San Miguel J, Hellmann A, Facon T, Foà R, Corso A, Masliak Z, Olesnyckyj M, Yu Z, Patin J, Zeldis JB, Knight RD. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. The New England journal of medicine. 2007 Nov 22; 357(21):2123-32.(Link to article – subscription may be required.)
